ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

  1. Garcia-Duran, C.
  2. Grau, F.
  3. Villacampa, G.
  4. Oaknin, A.
Aldizkaria:
International Journal of Gynecological Cancer

ISSN: 1525-1438,  1048-891X

Argitalpen urtea: 2022

Alea: 32

Zenbakia: 9

Orrialdeak: 1196-1200

Mota: Artikulua

DOI: 10.1136/IJGC-2022-003370 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus